Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-026 for Gout
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • 225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR+
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Financial Results
  • Stock Data
    • Analyst Coverage
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR+
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jan 19, 2021 10:10am EST

XORTX Provides Corporate Update; Synopsis of 2020 Achievements and Key Activities for 2021

Jan 19, 2021 6:55am EST

XORTX Provides Corporate Update

Jan 12, 2021 7:00am EST

XORTX Grants Options

Dec 29, 2020 7:00am EST

XORTX Announces Grant of European Patent

Nov 16, 2020 8:54am EST

XORTX Announces Topline Results from Mount Sinai’s COVID-19 Clinical Study

Oct 28, 2020 11:35am EDT

XORTX Participation in Virtual Conferences

Oct 23, 2020 6:34pm EDT

XORTX Reports Annual & Special Meeting Results

Oct 08, 2020 10:14am EDT

XORTX Receives Positive Feedback from FDA on COVID-19 Related Acute Kidney Injury

Sep 15, 2020 7:00am EDT

XORTX Highlights New Studies of Acute Kidney Disease Due to COVID-19 Infection

Aug 31, 2020 7:00am EDT

XORTX Files U.S. FDA Pre-IND Meeting Request for XRx-101 (Oxypurinol) COVID-19 Program and Pre-IND Meeting Submission

  • arrow_back
  • 1…
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2025 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap